Administration of sodium-glucose cotransporter-2 inhibitors in IgA nephropathy; a new strategy in the management?

Administration of sodium-glucose cotransporter-2 inhibitors in IgA nephropathy; a new strategy in the management?

Some of the several effects of sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including their metabolic, anti-inflammatory and hemodynamic properties, along with other kidney protective values, have directed clinicians to give these drugs in IgA-nephropathy (IgAN). According to recent studies...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of nephropathology 2023-02
Hauptverfasser: Ragati Haghi, Yeganeh, Dieti, Anastasia, Forootan, Majid
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title Journal of nephropathology
container_volume
creator Ragati Haghi, Yeganeh
Dieti, Anastasia
Forootan, Majid
description Some of the several effects of sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including their metabolic, anti-inflammatory and hemodynamic properties, along with other kidney protective values, have directed clinicians to give these drugs in IgA-nephropathy (IgAN). According to recent studies regarding the beneficial effects of SGLT-2i on IgAN, it is clear that clinicians are changing their approach towards kidney transplantation when it comes to aggressive immunosuppression. This mini-review aims towards the evaluation of the protective efficacy of SGLT-2i in IgA-nephropathy.
doi_str_mv 10.34172/jnp.2023.21429
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_34172_jnp_2023_21429</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_34172_jnp_2023_21429</sourcerecordid><originalsourceid>FETCH-LOGICAL-c819-a26583051ccfa4f6c2184c0ba549d21619bd8bb49476c72c62a8c2af437b410f3</originalsourceid><addsrcrecordid>eNo1kMFqwzAQREVpoSHNuVf9gBNpJcs2PZQQ2iYQ6CV3I8uSrRBLrqRQ8vd10nYvM8suw_AQeqZkyTgtYHV04xIIsCVQDtUdmgHkNCtLWt3_eybYI1rEeCTTVJyKvJihr3U7WGdjCjJZ77A3OPrWnoesO52VjxorP91cHH1IOmSArettY5MPcbJ4162x02Mf_ChTf3nBclq_8S1Pd5frS-o1HqSTnR60S69P6MHIU9SLP52jw_vbYbPN9p8fu816n6mpdCZB5CUjOVXKSG6EAlpyRRqZ86oFKmjVtGXT8IoXQhWgBMhSgTScFQ2nxLA5Wv3GquBjDNrUY7CDDJeakvrGrJ6Y1Vdm9Y0Z-wEtuWFV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Administration of sodium-glucose cotransporter-2 inhibitors in IgA nephropathy; a new strategy in the management?</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Ragati Haghi, Yeganeh ; Dieti, Anastasia ; Forootan, Majid</creator><creatorcontrib>Ragati Haghi, Yeganeh ; Dieti, Anastasia ; Forootan, Majid</creatorcontrib><description>Some of the several effects of sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including their metabolic, anti-inflammatory and hemodynamic properties, along with other kidney protective values, have directed clinicians to give these drugs in IgA-nephropathy (IgAN). According to recent studies regarding the beneficial effects of SGLT-2i on IgAN, it is clear that clinicians are changing their approach towards kidney transplantation when it comes to aggressive immunosuppression. This mini-review aims towards the evaluation of the protective efficacy of SGLT-2i in IgA-nephropathy.</description><identifier>ISSN: 2251-8363</identifier><identifier>EISSN: 2251-8819</identifier><identifier>DOI: 10.34172/jnp.2023.21429</identifier><language>eng</language><ispartof>Journal of nephropathology, 2023-02</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0001-6044-2677 ; 0000-0002-3691-2365 ; 0000-0002-8354-3662</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27923,27924</link.rule.ids></links><search><creatorcontrib>Ragati Haghi, Yeganeh</creatorcontrib><creatorcontrib>Dieti, Anastasia</creatorcontrib><creatorcontrib>Forootan, Majid</creatorcontrib><title>Administration of sodium-glucose cotransporter-2 inhibitors in IgA nephropathy; a new strategy in the management?</title><title>Journal of nephropathology</title><description>Some of the several effects of sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including their metabolic, anti-inflammatory and hemodynamic properties, along with other kidney protective values, have directed clinicians to give these drugs in IgA-nephropathy (IgAN). According to recent studies regarding the beneficial effects of SGLT-2i on IgAN, it is clear that clinicians are changing their approach towards kidney transplantation when it comes to aggressive immunosuppression. This mini-review aims towards the evaluation of the protective efficacy of SGLT-2i in IgA-nephropathy.</description><issn>2251-8363</issn><issn>2251-8819</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNo1kMFqwzAQREVpoSHNuVf9gBNpJcs2PZQQ2iYQ6CV3I8uSrRBLrqRQ8vd10nYvM8suw_AQeqZkyTgtYHV04xIIsCVQDtUdmgHkNCtLWt3_eybYI1rEeCTTVJyKvJihr3U7WGdjCjJZ77A3OPrWnoesO52VjxorP91cHH1IOmSArettY5MPcbJ4162x02Mf_ChTf3nBclq_8S1Pd5frS-o1HqSTnR60S69P6MHIU9SLP52jw_vbYbPN9p8fu816n6mpdCZB5CUjOVXKSG6EAlpyRRqZ86oFKmjVtGXT8IoXQhWgBMhSgTScFQ2nxLA5Wv3GquBjDNrUY7CDDJeakvrGrJ6Y1Vdm9Y0Z-wEtuWFV</recordid><startdate>20230204</startdate><enddate>20230204</enddate><creator>Ragati Haghi, Yeganeh</creator><creator>Dieti, Anastasia</creator><creator>Forootan, Majid</creator><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0001-6044-2677</orcidid><orcidid>https://orcid.org/0000-0002-3691-2365</orcidid><orcidid>https://orcid.org/0000-0002-8354-3662</orcidid></search><sort><creationdate>20230204</creationdate><title>Administration of sodium-glucose cotransporter-2 inhibitors in IgA nephropathy; a new strategy in the management?</title><author>Ragati Haghi, Yeganeh ; Dieti, Anastasia ; Forootan, Majid</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c819-a26583051ccfa4f6c2184c0ba549d21619bd8bb49476c72c62a8c2af437b410f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ragati Haghi, Yeganeh</creatorcontrib><creatorcontrib>Dieti, Anastasia</creatorcontrib><creatorcontrib>Forootan, Majid</creatorcontrib><collection>CrossRef</collection><jtitle>Journal of nephropathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ragati Haghi, Yeganeh</au><au>Dieti, Anastasia</au><au>Forootan, Majid</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Administration of sodium-glucose cotransporter-2 inhibitors in IgA nephropathy; a new strategy in the management?</atitle><jtitle>Journal of nephropathology</jtitle><date>2023-02-04</date><risdate>2023</risdate><issn>2251-8363</issn><eissn>2251-8819</eissn><abstract>Some of the several effects of sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including their metabolic, anti-inflammatory and hemodynamic properties, along with other kidney protective values, have directed clinicians to give these drugs in IgA-nephropathy (IgAN). According to recent studies regarding the beneficial effects of SGLT-2i on IgAN, it is clear that clinicians are changing their approach towards kidney transplantation when it comes to aggressive immunosuppression. This mini-review aims towards the evaluation of the protective efficacy of SGLT-2i in IgA-nephropathy.</abstract><doi>10.34172/jnp.2023.21429</doi><orcidid>https://orcid.org/0000-0001-6044-2677</orcidid><orcidid>https://orcid.org/0000-0002-3691-2365</orcidid><orcidid>https://orcid.org/0000-0002-8354-3662</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2251-8363
ispartof Journal of nephropathology, 2023-02
issn 2251-8363
2251-8819
language eng
recordid cdi_crossref_primary_10_34172_jnp_2023_21429
source DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals
title Administration of sodium-glucose cotransporter-2 inhibitors in IgA nephropathy; a new strategy in the management?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T15%3A44%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Administration%20of%20sodium-glucose%20cotransporter-2%20inhibitors%20in%20IgA%20nephropathy;%20a%20new%20strategy%20in%20the%20management?&rft.jtitle=Journal%20of%20nephropathology&rft.au=Ragati%20Haghi,%20Yeganeh&rft.date=2023-02-04&rft.issn=2251-8363&rft.eissn=2251-8819&rft_id=info:doi/10.34172/jnp.2023.21429&rft_dat=%3Ccrossref%3E10_34172_jnp_2023_21429%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true